Business Description
Caliway Biopharmaceuticals Co Ltd
ISIN : TW0006919004
Description
Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its leading candidate, CBL-514, is a new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 181.42 | |||||
| Equity-to-Asset | 0.98 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 370.74 | |||||
| Beneish M-Score | -0.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17.4 | |||||
| 3-Year EBITDA Growth Rate | -37.8 | |||||
| 3-Year EPS without NRI Growth Rate | -28.8 | |||||
| 3-Year FCF Growth Rate | -55.6 | |||||
| 3-Year Book Growth Rate | 294.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 94.41 | |||||
| 9-Day RSI | 80.29 | |||||
| 14-Day RSI | 65.94 | |||||
| 6-1 Month Momentum % | -4.59 | |||||
| 12-1 Month Momentum % | 13.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 50.81 | |||||
| Quick Ratio | 50.8 | |||||
| Cash Ratio | 50.37 | |||||
| Days Inventory | 75.77 | |||||
| Days Sales Outstanding | 53.71 | |||||
| Days Payable | 69.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.3 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.56 | |||||
| Operating Margin % | -1318.88 | |||||
| Net Margin % | -1254.64 | |||||
| FCF Margin % | -1113.8 | |||||
| ROE % | -25.18 | |||||
| ROA % | -24.24 | |||||
| ROIC % | -493.47 | |||||
| ROC (Joel Greenblatt) % | -546.46 | |||||
| ROCE % | -24.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 970.33 | |||||
| PB Ratio | 7.92 | |||||
| Price-to-Tangible-Book | 7.91 | |||||
| EV-to-EBIT | -114.2 | |||||
| EV-to-EBITDA | -121.11 | |||||
| EV-to-Revenue | 1431.27 | |||||
| EV-to-FCF | -113.55 | |||||
| Price-to-Net-Current-Asset-Value | 8.09 | |||||
| Price-to-Net-Cash | 8.16 | |||||
| Earnings Yield (Greenblatt) % | -0.87 | |||||
| FCF Yield % | -0.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Caliway Biopharmaceuticals Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 38.932 | ||
| EPS (TTM) (NT$) | -3.94 | ||
| Beta | 0 | ||
| Volatility % | 84.07 | ||
| 14-Day RSI | 65.94 | ||
| 14-Day ATR (NT$) | 14.291657 | ||
| 20-Day SMA (NT$) | 386.15 | ||
| 12-1 Month Momentum % | 13.43 | ||
| 52-Week Range (NT$) | 240.5 - 560 | ||
| Shares Outstanding (Mil) | 139.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Caliway Biopharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Caliway Biopharmaceuticals Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Caliway Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Caliway Biopharmaceuticals Co Ltd(ROCO:6919)'s stock price today?
The current price of ROCO:6919 is NT$425.00. The 52 week high of ROCO:6919 is NT$560.00 and 52 week low is NT$240.50.
When is next earnings date of Caliway Biopharmaceuticals Co Ltd(ROCO:6919)?
The next earnings date of Caliway Biopharmaceuticals Co Ltd(ROCO:6919) is .
Does Caliway Biopharmaceuticals Co Ltd(ROCO:6919) pay dividends? If so, how much?
Caliway Biopharmaceuticals Co Ltd(ROCO:6919) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers